LIVE WebinarMonday, December 6, 20213:00 – 4:30 PM Eastern TimeRegister NowEarly cancer detection is a crucial determinant of patient survival, but scientists battle to identify diagnostic tools and reliable biomarkers. Researchers just recently discovered cancer-specific glycosylation signatures that promote growth progression. Transformed glycosylation states render cancer cells more intrusive because protein glycosylation controls cellular behaviors such as cell-adhesion and migration. In this webinar, brought to you by Vector Laboratories, Karen Abbott and Susan Bellis will talk about how cancer cells customize glycosylation paths to endure, and how to target tumor-specific glycans for early cancer detection, diagnosis, and healing development.Topics to be coveredTools and technologies to discover glycan biomarkersHow cancer-induced receptor glycosylation activates tumorigenic pathwaysThe therapeutic capacity of tumor-selective glycansRegister NowMeet the Speakers: Karen Abbott, PhDAssociate ProfessorDepartment of Translational MedicineHerbert Wertheim College of MedicineFlorida International UniversitySusan L. Bellis, PhDProfessorDepartment of Cell, Developmental, and Integrative BiologyUniversity of Alabama at BirminghamSponsored By